Novonesis Raises 2026 Outlook After 8% H1 Sales Growth
Event summary
- Novonesis reported 8% organic sales growth in H1 2026, with Q2 growth at 9%.
- Adjusted EBITDA margin improved to 37.7%, up 30bps year-over-year.
- Company raised full-year organic sales growth outlook to 7-8% (from 5-7%).
- Inaugural EUR 1 billion share buyback program approved for H2 2026–2029.
- Agreement signed to acquire remaining 77% of MicroBioGen.
The big picture
Novonesis's strong H1 performance reflects growing demand for biosolutions, particularly in Food & Health and Household Care segments. The raised outlook and buyback program signal confidence in operational resilience, though geopolitical exits pose a wildcard. The MicroBioGen deal underscores strategic focus on Planetary Health expansion.
What we're watching
- Execution Risk
- Whether Novonesis can sustain 7-8% organic growth amid geopolitical exits.
- Capital Allocation
- The pace at which the EUR 1 billion buyback program unfolds.
- Integration Challenge
- How MicroBioGen acquisition impacts Planetary Health Biosolutions.
Related topics